PURPOSE: Several observational studies have indicated that vitamin D receptor activators (VDRA), including paricalcitol, are associated with greater survival in maintenance hemodialysis (MHD) patients. However, patients with higher serum parathyroid hormone, a surrogate of higher death risk, are usually given higher VDRA doses, which can lead to confounding by indication and attenuate the expected survival advantage of high VDRA doses. METHODS: We examined mortality-predictability of low (>1 but <10 µg/week) versus high (≥10 µg/week) dose of administered paricalcitol over time in a contemporary cohort of 15 442 MHD patients (age 64 ± 15 years, 55% men, 44% diabetes, 35% African-Americans) from all DaVita dialysis clinics across the USA (7/2001-6/2006 with survival follow-ups until 6/2007) using conventional Cox regression, propensity score (PS) matching, and marginal structural model (MSM) analyses. RESULTS: In our conventional Cox models and PS matching models, low dose of paricalcitol was not associated with mortality either in baseline (hazard ratio (HR): 1.03, 95% confidence interval (CI): (0.97-1.09)) and (HR: 0.99, 95%CI:(0.86-1.14)) or time-dependent (HR: 1.04, 95%CI: (0.98-1.10)) and (HR: 1.12, 95%CI: (0.98-1.28)) models, respectively. In contrast, compared to high dose of paricalcitol, low dose was associated with a 26% higher risk of mortality (HR: 1.26, 95%CI: (1.19-1.35)) in MSM. The association between dose of paricalcitol and mortality was robust in almost all subgroups of patients using MSMs. CONCLUSIONS: Higher dose of paricalcitol appears causally associated with greater survival in MHD patients. Randomized controlled trials need to verify the survival effect of paricalcitol dose in MHD patients are indicated.
PURPOSE: Several observational studies have indicated that vitamin D receptor activators (VDRA), including paricalcitol, are associated with greater survival in maintenance hemodialysis (MHD) patients. However, patients with higher serum parathyroid hormone, a surrogate of higher death risk, are usually given higher VDRA doses, which can lead to confounding by indication and attenuate the expected survival advantage of high VDRA doses. METHODS: We examined mortality-predictability of low (>1 but <10 µg/week) versus high (≥10 µg/week) dose of administered paricalcitol over time in a contemporary cohort of 15 442 MHD patients (age 64 ± 15 years, 55% men, 44% diabetes, 35% African-Americans) from all DaVita dialysis clinics across the USA (7/2001-6/2006 with survival follow-ups until 6/2007) using conventional Cox regression, propensity score (PS) matching, and marginal structural model (MSM) analyses. RESULTS: In our conventional Cox models and PS matching models, low dose of paricalcitol was not associated with mortality either in baseline (hazard ratio (HR): 1.03, 95% confidence interval (CI): (0.97-1.09)) and (HR: 0.99, 95%CI:(0.86-1.14)) or time-dependent (HR: 1.04, 95%CI: (0.98-1.10)) and (HR: 1.12, 95%CI: (0.98-1.28)) models, respectively. In contrast, compared to high dose of paricalcitol, low dose was associated with a 26% higher risk of mortality (HR: 1.26, 95%CI: (1.19-1.35)) in MSM. The association between dose of paricalcitol and mortality was robust in almost all subgroups of patients using MSMs. CONCLUSIONS: Higher dose of paricalcitol appears causally associated with greater survival in MHD patients. Randomized controlled trials need to verify the survival effect of paricalcitol dose in MHD patients are indicated.
Authors: Kamyar Kalantar-Zadeh; Elani Streja; Csaba P Kovesdy; Antigone Oreopoulos; Nazanin Noori; Jennie Jing; Allen R Nissenson; Mahesh Krishnan; Joel D Kopple; Rajnish Mehrotra; Stefan D Anker Journal: Mayo Clin Proc Date: 2010-11 Impact factor: 7.616
Authors: Nazanin Noori; Csaba P Kovesdy; Ramanath Dukkipati; Usama Feroze; Miklos Z Molnar; Rachelle Bross; Allen R Nissenson; Joel D Kopple; Keith C Norris; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2011-02-04 Impact factor: 3.754
Authors: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress Journal: Lancet Date: 2010-11-06 Impact factor: 79.321
Authors: Christian S Shinaberger; Joel D Kopple; Csaba P Kovesdy; Charles J McAllister; David van Wyck; Sander Greenland; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2008-08-13 Impact factor: 8.237
Authors: Pooneh Alborzi; Nina A Patel; Carla Peterson; Jennifer E Bills; Dagim M Bekele; Zerihun Bunaye; Robert P Light; Rajiv Agarwal Journal: Hypertension Date: 2008-07-07 Impact factor: 10.190
Authors: Robert D Gibbons; Marcelo Coca Perraillon; Kwan Hur; Rena M Conti; Robert J Valuck; David A Brent Journal: Pharmacoepidemiol Drug Saf Date: 2014-09-29 Impact factor: 2.890
Authors: Paungpaga Lertdumrongluk; Elani Streja; Connie M Rhee; Jongha Park; Onyebuchi A Arah; Steven M Brunelli; Allen R Nissenson; Daniel Gillen; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2014-04-26 Impact factor: 3.754
Authors: Bryan B Shapiro; Elani Streja; Connie M Rhee; Miklos Z Molnar; Leeka Kheifets; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Hemodial Int Date: 2014-01-15 Impact factor: 1.812
Authors: Miklos Z Molnar; Kamyar Kalantar-Zadeh; Evan H Lott; Jun Ling Lu; Sandra M Malakauskas; Jennie Z Ma; Darryl L Quarles; Csaba P Kovesdy Journal: J Am Coll Cardiol Date: 2013-11-21 Impact factor: 24.094